- 2013
- Press releases - 02.12.2013
A new Associated International Laboratory on the trail of an ‘electronic nose’ to sniff out Pulmonary Hypertension
Professor André Syrota, Inserm Chief Executive, and Professor Peretz Lavie, President of Technion, will sign the agreement to create a new Associated International Laboratory (AIL) on 17 December 2013. This artificial ‘electronic nose’ project brings together Inserm Unit 999 ‘Pulmonary Hypertension’ and the Russell Berrie Nanotechnology Institute Chemical Engineering department, directed by Professor Hossam Haick.
- Press releases - 28.11.2013
Maternal mortality: a reduction in deaths from haemorrhage
The new report, “Maternal Mortality in France,” coordinated by Inserm Unit U953, Epidemiological Research Unit on Perinatal Health and Women’s and Children’s Health, announces a reduction in the rate of mortality due to postpartum haemorrhage—the leading cause of maternal mortality in France—for the 2007-2009 data compared to 2004-2006.
- Press releases - 28.11.2013
Clinical trial launched to treat Sanfilippo B syndrome using gene therapy
A phase I/II gene therapy clinical trial for children suffering from Sanfilippo B syndrome, a rare genetic disease, enrolled a first patient in October of this year.
- Press releases - 27.11.2013
Mechanics and genetics: an indispensable cocktail for embryonic development
In the fruit fly Drosophila and zebrafish, mechanical strain may activate the genetic cascade that initiates the formation of the future organs during embryogenesis. A discovery made by Emmanuel Farge (Inserm Research Director at Institut Curie) and his staff might explain the emergence of the first complex organisms more than 570 million years ago.
- What's on? - 27.11.2013
30 years of aids research
AIDS stands for acquired immunodeficiency syndrome. This sexually transmitted infection is caused by a virus called HIV which attacks the immune system, making the body less resistant to normally benign diseases.WHO reports that more and more adolescents are affected by AIDS. “Over two million adolescents aged 10 to 19 live with HIV, and many of […]
- What's on? - 25.11.2013
1 December 2013: World AIDS Day
What research progress has been made? According to the WHO, 34 million people are currently infected by HIV. Only 1.3 million patients from poor countries have access to treatment and there are 6,800 new cases of HIV each day. The Human Immunodeficiency Virus (HIV) attacks the cells in the immune system, either destroying them or […]
- Press releases - 22.11.2013
Stanislas Dehaene is awarded the Inserm Grand Prix for 2013
The annual Inserm awards ceremony will take place on Monday 2 December at the Collège de France. On this occasion, eight prizes will be awarded to women and men who contribute daily to the scientific excellence of the Institute.
Stanislas Dehaene will be awarded the Inserm Grand Prix for his body of work on consciousness, Ogobara Doumbo will receive the International Prize for his research on malaria, and Daniel Louvard will be awarded the Honorary Prize for his work on cancer. - Press releases - 22.11.2013
Chemotherapy: when our intestinal bacteria provide reinforcement
Research jointly conducted by investigators at Institut Gustave Roussy, Inserm, Institut Pasteur and INRA (French National Agronomic Research Institute) has led to a rather surprising discovery on the manner in which cancer chemotherapy treatments act more effectively with the help of the intestinal flora (also known as the intestinal microbiota).
- Press releases - 21.11.2013
Where and how are fear-related behaviours and anxiety disorders controlled?
A team of researchers at Inserm led by Cyril Herry (Inserm Unit 862, “Neurocentre Magendie,” Bordeaux) has just shown that interneurons located in the forebrain at the level of the prefrontal cortex are heavily involved in the control of fear responses. Using an approach combining in vivo recordings and optogenetic manipulations in mice, the researchers succeeded in showing that the inhibition of parvalbumin-expressing prefrontal interneurons triggers a chain reaction resulting in fear behaviour.
- Press releases - 18.11.2013
Cancer treatment: a step towards personalized chronotherapy
An international study conducted on mice and coordinated by researchers from Inserm, CNRS and Université Paris-Sud[1] has paved the way towards personalized chronotherapy treatments. In an article published in the journal Cancer Research, the team has shown that the timing of optimal tolerance to irinotecan, a widely used anti-cancer drug, varies by 8 hours depending on the sex and genetic background of mice. They then developed a mathematical model that makes it possible to predict, for each animal, the optimal timing for administering the drug.